Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library
Fast recruiting clinical trials – a Utopian dream or logistical nightmare? | British Journal of Cancer
Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment | TCRM
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Protocol Phase 1 Template
PDF) Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
Clinical Trials - Cue Biopharma
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma | Haematologica
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors | PLOS ONE
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis
Cureus | A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19
Cureus | A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
CLINICAL STUDY PROTOCOL
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. - Abstract - Europe PMC
Spotlight on pomalidomide: could less be more? | Leukemia
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. - Abstract - Europe PMC
Cureus | A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors | PLOS ONE
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa - Santagostino - 2014 - Haemophilia - Wiley Online Library
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
